Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Active Pharmaceutical Ingredient (API)	338.34M	356.16M	554.61M	426.89M	464.61M
Active Pharmaceutical Ingredient (API) Growth	-5.00%	-35.78%	29.92%	-8.12%	-15.23%
Preparations	107.46M	85.21M	103.38M	86.47M	75.13M
Preparations Growth	26.11%	-17.57%	19.56%	15.08%	69.63%
Others	7.50M	4.49M	5.04M	1.56M	872.97K
Others Growth	66.94%	-10.75%	223.45%	78.36%	54.07%
Total	453.31M	445.86M	663.03M	514.91M	540.62M
Total Growth	1.67%	-32.75%	28.76%	-4.76%	-8.82%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
China	250.64M	236.99M	410.77M	277.03M	266.14M
China Growth	5.76%	-42.30%	48.27%	4.09%	48.89%
Overseas	202.66M	208.87M	252.26M	237.88M	274.48M
Overseas Growth	-2.97%	-17.20%	6.04%	-13.34%	-33.73%
Total	453.31M	445.86M	663.03M	514.91M	540.62M
Total Growth	1.67%	-32.75%	28.76%	-4.76%	-8.82%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 3, 2026

Data Sources Report a data error